Podcasts about kromek

This week on The Sunday Roast, Phil Carroll, Kevin Hornsby, and Charles Archer break down the latest market moves and trends in the small-cap space. They welcome Daniel Gee from Priority Intelligence to discuss the AI shake-up following DeepSeek and Alibaba's latest breakthroughs, as well as Priority's new partnership with Funding Circle. Also joining the show is Jonathan Bixby, newly appointed Executive Director at Tiger Royalties & Investments, to discuss Tiger's strategic pivot into the tech sector with the acquisition of Bixby Technology Inc. The team also covers the top movers and shakers in the small-cap market, exploring standout performances from Zenith Energy and Kromek, as well as key failures. To round things off, they review this week's must-watch TV, including American Primeval and Out There. 00:00 - 00:10:19 Weekly News Roundup  00:10:19 #PR1 Interview 00:34:45 #TIR Interview  00:59:05 #ZEN     01:02:52 #KMK   01:06:24 #FUM  01:06:49 #MET1  01:10:04 #CGNR  01:11:15 #CMET  01:12:35 #GGP  01:12:53 #GMET  01:14:03 #BZT  01:17:45 #AFP  01:18:27 #ARCM  01:20:21  TV recommendations Disclaimer & Declaration of Interest This podcast may contain paid promotions, including but not limited to sponsorships, endorsements, or affiliate partnerships. The information, investment views, and recommendations provided are for general informational purposes only and should not be construed as a solicitation to buy or sell any financial products related to the companies discussed. Any opinions or comments are made to the best of the knowledge and belief of the commentators; however, no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion. Listeners are encouraged to perform their own research and consult with a licensed professional before making any financial decisions based on the content of this podcast. 

Kromek Group PLC CEO Arnab Basu joined Proactive's Stephen Gunnion with a breakdown of the company's first-half financial and operational performance. The company reported increased revenue, improved gross margin, and a notably reduced loss in the first half of the year. Basu attributed this progress to a focus on profitability through cost control and enhanced business margins. He emphasized the growth in advanced imaging and CBRN (Chemical, Biological, Radiological, and Nuclear defense) segments as key drivers. In Advanced Imaging, Kromek is gaining traction in medical imaging, particularly in SPECT (nuclear medicine modality) and CT (diagnostic imaging). The company has seen a shift towards the adoption of its CZT material in these sectors, enhancing digital spectrums and CT capabilities. This advancement is marked by new product launches and significant partnerships, including with a CT Original Equipment Manufacturer (OEM). Additionally, Spectrum Dynamics, a key customer, launched a new product that enhances market and user capabilities. The CBRN segment is growing due to heightened global security concerns and the demand for handheld radiation detection tools. Kromek has secured contracts and developed strong pipelines in this area, including partnerships for biosecurity projects with the US and UK governments. Looking ahead, Basu remains optimistic about Kromek's growth trajectory, expecting record revenues and continued focus on cost control and margin improvement for the full year 2024. ‌ #KromekGroupPLC #ArnabBasu #ProactiveLondon #FinancialGrowth #RevenueGrowth #AdvancedImaging #CBRN #MedicalImaging #SPECT #CTScans #PhotonCountingCT #RadiationDetection #SecurityTechnology #Biosecurity #NuclearMedicine #DiagnosticImaging #HealthcareTechnology #Innovation #BusinessStrategy #FinancialHighlights #GrowthDrivers #TechIndustry #CorporateInterview #CEOInterview #BusinessNews #TechnologyAdvancements #DefenseTechnology #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

London's FTSE 100 slipped early on, ahead of the European Central Bank's latest interest rate call and US GDP figures on Thursday. Among equities, Wizz Air was one of many to report this morning, with shares in the airline taking a hit after it swung to a loss during the third quarter. Halfords shares also fell, as the retailer backed full-year guidance but unveiled below-expected third-quarter sales. Things were more positive for Dr Martens' stock, as shares climbed on news that tough trading in the three months to December was in line with expectations. Haleon also edged higher early on after announcing the sale of its ChapStick brand to Suave Brands Co to pay down debt. And finally, radiation and bio-detection tech developer Kromek soared after unveiling a £1.4 million order from the EU. #ProactiveInvestors #market report #wizzair #halfords #drmartens #haleon #kromek #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

The FTSE 100 was on the back foot again after US tech stocks tanked as Google owner Alphabet took a beating after its latest results. That led to tech-heavy US index Nasdaq having its worst day since February, which dragged on London with Footsie down 49 at 7,364 in early trades. Standard Chartered led the retreat as the Asia-focused bank reported a sharp drop in profit in the third quarter, taking a hit from its exposure to Chinese banking and real estate, although the bank backed its annual guidance. WPP was also under pressure as the ad agency warned full-year revenue and profit margins would be lower than expected, as advertising spending fell in North America and China remained weak. Slightly better was Marmite and Ben & Jerry's owner Unilever, which reported price growth continued to ease in the third quarter as it unveiled a 5.2% rise in underlying sales. A takeover battle might be on the way at Wagamama owner Restaurant Group with Pizza Express said to be interested in taking it away. Restaurant has already agreed a £500m bid from private equity group Apollo. Among the small caps, Kromek shares marched 24% higher after it reported winning a US$5.9m contract from the US Department of Homeland Security (DHS) to research and develop biosecurity technologies. #ProactiveInvestors #marketreport #ftse100 #nasdaq #alphabet #google #standardcharteredbank #wpp #unilever #pizzaexpress #wagamama #kromek #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Kromek Group PLC (AIM:KMK) CEO Arnab Basu speaks to Thomas Warner from Proactive after releasing final results for the year ended 30 April 2023, a period he describes as "in many ways a landmark year for Kromek." Basu says that it was a year of "very strong growth" and gives an overview of how it was achieved, speaking with reference to the group's post-Covid "growth journey." He also highlights what he calls a significant improvement in margins and notes that much of the revenue growth came from product sales, indicating a shift away from development contracts. Looking ahead, Basu suggests that Kromek's sectors remain strong, with advanced imaging benefiting from an ageing population's demand for better healthcare and the need for improved diagnostics. On the other side of the business, Basu is also upbeat on the prospects for Kromek's Chemical, Biological, Radiological and Nuclear (CBRN) arm due to increasing security demands driven by global political instabilities. #ProactiveInvestors #KromekGroup #CEOInterview #BusinessGrowth #RevenueGrowth #TransformativeYear #LandmarkYear #AdvancedImaging #CBRN #MedicalImaging #PhotonCounting #Healthcare #SecurityServices #GlobalPolitics #DefenceSpending #SustainableGrowth #EBITDA #Commercialization #ProductTraction #CustomerWins #MarketDrivers #FutureOutlook #InvestmentOpportunity #ProactivInterview #ProactivShow #BusinessNews #Technology #Innovation #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Kromek Group PLC (AIM:KMK) CEO Arnab Basu speaks to Proactive after announcing the signing of several new contracts during the final months of 2022. Basu says he is "delighted" by the new contracts and expects to meet the stated target of achieving 45% year-on-year on growth in revenues. #ProactiveInvestors #Kromek #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

The FTSE 100 was steady this morning at around 7,380 points. Fresh data from the office for national statistics showed that the cost of energy helped bring UK inflation to 41-year highs of 11.1% in October. Deliveroo said its “disciplined approach to capital allocation” means that it has decided to stop trading in Australia, but is keeping its full-year guidance unchanged. Google owner Alphabet is facing calls from one of its investors to make ‘aggressive' cuts to its wage bill. Sir Christopher Hohn, managing director at TCI, holds a stake worth US$6bn in the company. Scottish energy company SSE reported a pre-tax loss of £511mln in its half year results due to weak renewables performance, but still increased its interim dividend by 13.7%. Radiation protection equipment maker Kromek says its won a £5mln UK government department contract to develop and supply biological threat detection systems. Work will commence in December on the three-year programme. Ethernity Networks picked up another follow-on order for its 5G second-generation wireless base station node. The new order is to support network functions and critical traffic management. And East Star Resources said its completed a 1,001-metre reverse circulation drilling programme at the Talairyk project in Kazakhstan. #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

The FTSE 100 was virtually unchanged this morning at around 7,300 points. British Gas owner Centrica is forecasting that full year earnings-per-share will be towards the top end of City expectations. WH Smith has swung to a profit for the year ending 31 August 2022 and has reinstated its dividend saying it is now in “its strongest ever position as a global travel retailer”. Consumer healthcare player Haleon expects growth in organic revenue and profits this year – the Sensodyne and Panadol maker said it benefited from increasing its prices to offset cost inflation. Gold explorer Ariana Resources says its made “substantial progress” on its advanced projects in Turkey, performing in line with guidance after over 11,000 meters of drilling. Radiation detector maker Kromek said it has received and delivered a contract worth US$1.3mln from a US customer for its D3M wearable detection device. It also forecasted 45% revenue growth for the first half of the financial year. And Pantheon added to its acreage in Alaska with the acquisition of approximately another 40,000 acres on the North Slope.

Phil Carroll and Kevin Hornsby talk to Arnab about Kromek's cutting-edge radiation detection technology, with many of its products based on cadmium zinc telluride (CZT), which has a unique combination of properties that enable colour and digital detection of radiation for Homeland Security, medical, industrial and laboratory applications. Companies mentioned (in no particular order) #KMK #BRES #SVML #BEN #CMRS #BZT #CLON #ORCA Disclaimer & Declaration of Interest The information, investment views, and recommendations in this podcast are provided for general information purposes only. Nothing in this podcast should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the commentator but no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion.

Kromek Group Plc chief executive Arnab Basu joins Katie to talk about the company's trading update, covering the period to the end of April, ahead of July's results. Basu gives his insights to Kromek's rapidly quickening momentum through the second half the fiscal year. Kromek provides design and high-volume supply of both hardware and software of CZT solid-state radiation detectors and scintillation radiation detector components and finished products. It supplies the medical OEM, civil nuclear and security sectors.

A look at Kromek and NETPark Sedgefield where it is based

Kromek Group PLC (LON:KMK) Arnab Basu talks to Proactive London about being awarded a contract by the US Defense Advanced Research Projects Agency (DARPA) for Phase II development of its biological threat detection system. Phase II is worth US$6mln and will see the company develop an automated wide spectrum airborne pathogen detection system that is fully mobile and runs autonomously. The new deal follows the successful completion of Phase I of development, which included the creation of a vehicle-mounted biological-threat identifier as well as a miniaturised mobile wide-area bio-surveillance system.

Kromek Group PLC (LON:KMK) CEO Arnab Basu talks to Proactive London's Katie Pilbeam about their revenue and EBITDA expectations for the year ended 30 April 2021 that are in line with market expectations. Arnab talks through orders and shipments of the company's medical, nuclear and security screening detection technology which resumed in the final two months of the first half of the year. This momentum continued throughout the second half as Kromek delivered on previously awarded contracts and won new orders. His message is, 'we are back on track, as commercial activities really ramp up'.

This month, Richard talks to Dr. Arnab Basu, CEO of Kromek Group Plc. Kromek is an international AIM-listed technology business involved in the development and supply of high-performance radiation detection products and other advanced technologies. In this episode, Arnab talks through the challenges of building Kromek, international attitudes to innovation and the value of STEM education at all ages.

Kevin sits down with Kevin Good of Kromek to discuss the D3S ID which is a wearable RIID that is both the fastest and most accurate isotope ID device on the market. The device helps first responders detect dirty bombs.

In one of our most in-depth interviews to date, we spoke with Dr Arnab Basu, CEO of AIM-listed Kromek Group Plc #KMK. Kromek Group operate in the medical imaging, nuclear detection, and security screening environments and have announced significant contract wins throughout 2017 to the financial markets. We delved deep in to what it is that is driving company growth and asked how they are going about it by reflecting on recent board appointments, director share purchases, and the ongoing support from institutional backers. Thank you to Dr Basu for providing such depth and we welcome any feedback on this podcast that investors (or potential investors) may have to enquiries@share-talk.com

Bdellovibrio is a small bacterium which preys and kills other bacteria. A team of researchers in the UK has shown in animal experiments that injections of the predator microbe can successfully treat infections. So how close does this take us to Bdellovibrio therapy for human patients and what part might it play in tackling the growing crisis of antibiotic resistance? Adam Rutherford talks to Professor Liz Sockett of the University of Nottingham. The British government has announced that it will be spending an additional £2 billion on research and development by 2020. Commentators say it is the largest hike in public funding for science in a very long time. Dr Sarah Main of the Campaign for Science and Engineering, and Dr Arnab Basu, physicist and CEO of Kromek, discuss the new money and how it would be best used. Also in the programme, materials and electronics engineers in the US have devised a small wearable heart monitor - the size and thickness of a sticking plaster. Adam talks to its lead designer Professor John Rogers of Northwestern University in Chicago. And could phobias be cured without exposure to the thing which frightens people? Dr Ben Seymour outlines an intriguing experiment which involved reading people's thoughts in a brain scanner, which suggests ultimately it may be possible.

Arnab Basu CEO and Derek Bulmer CFO of #Kromek plc talk about increased #revenues and positive expectations for 2015 Kromek is a supplier of patented radiation detection technologies to the #Medical Imaging, #Nuclear Detection and #Security Screening markets. #Trading #Stocks #LSE